Design and Synthesis of Novel Indole Ethylamine Derivatives as a Lipid Metabolism Regulator Targeting PPARα/CPT1 in...

Area of Science:

• Biochemistry
• Pharmacology
• Hepatology

Background:

• Nonalcoholic fatty liver disease (NAFLD) is a growing health concern linked to dysregulated lipid metabolism.
• Peroxisome proliferator-activated receptor alpha (PPARα) and carnitine palmitoyltransferase 1 (CPT1) are key regulators of lipid metabolism and potential therapeutic targets for NAFLD.

Purpose of the Study:

• To design, synthesize, and evaluate novel indole ethylamine derivatives as potential modulators of lipid metabolism for NAFLD therapy.
• To investigate the efficacy of synthesized compounds, particularly compound 9, in activating PPARα and CPT1a and reducing lipid accumulation in vitro.

Main Methods:

• Synthesis of novel indole ethylamine derivatives.
• In vitro assays using oleic acid (OA)-induced AML12 cells to assess lipid accumulation.
• Measurement of intracellular triglyceride levels.
• Analysis of gene and protein expression, including hormone-sensitive triglyceride lipase (HSL), adipose triglyceride lipase (ATGL), and acetyl-CoA carboxylase (ACC) phosphorylation.

Main Results:

• Compound 9 demonstrated significant activation of PPARα and CPT1a.
• Treatment with compound 9 dose-dependently reduced intracellular triglyceride levels in OA-induced AML12 cells, outperforming the PPARα agonist fenofibrate.
• Compound 9 upregulated the expression of HSL and ATGL and increased ACC phosphorylation, indicating enhanced fatty acid oxidation and reduced lipogenesis.

Conclusions:

• The novel indole ethylamine derivative, compound 9, exhibits dual-target efficacy in regulating lipid metabolism by activating PPARα and CPT1a.
• Compound 9 effectively reduces lipid accumulation in hepatocytes and modulates key enzymes involved in fatty acid metabolism.
• This compound represents a promising drug lead for the development of novel therapeutic strategies for nonalcoholic fatty liver disease.